LLY

1,013.92

+2.52%↑

JNJ

194.22

+0.63%↑

UNH

340.11

+4%↑

NVS

131.67

+0.84%↑

ABT

128.96

+1.61%↑

LLY

1,013.92

+2.52%↑

JNJ

194.22

+0.63%↑

UNH

340.11

+4%↑

NVS

131.67

+0.84%↑

ABT

128.96

+1.61%↑

LLY

1,013.92

+2.52%↑

JNJ

194.22

+0.63%↑

UNH

340.11

+4%↑

NVS

131.67

+0.84%↑

ABT

128.96

+1.61%↑

LLY

1,013.92

+2.52%↑

JNJ

194.22

+0.63%↑

UNH

340.11

+4%↑

NVS

131.67

+0.84%↑

ABT

128.96

+1.61%↑

LLY

1,013.92

+2.52%↑

JNJ

194.22

+0.63%↑

UNH

340.11

+4%↑

NVS

131.67

+0.84%↑

ABT

128.96

+1.61%↑

Search

Cencora Inc

Open

SectorGezondheidszorg

364.88 0.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

358.14

Max

365.96

Belangrijke statistieken

By Trading Economics

Inkomsten

-28M

690M

Verkoop

5.2B

81B

K/W

Sectorgemiddelde

34.967

77.256

EPS

4

Dividendrendement

0.64

Winstmarge

0.855

Werknemers

51,000

EBITDA

-56M

1.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+7.99% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.64%

2.33%

Volgende dividenddatum

1 dec 2025

Volgende Ex Dividend datum

14 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

9.2B

66B

Vorige openingsprijs

364.73

Vorige sluitingsprijs

364.88

Nieuwssentiment

By Acuity

45%

55%

163 / 374 Rangschikking in Healthcare

Cencora Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2025, 23:59 UTC

Winsten

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Winsten

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Winsten

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Winsten

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Winsten

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Winsten

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Winsten

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Winsten

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Winsten

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Marktinformatie

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Winsten

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Winsten

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Winsten

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Winsten

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q EPS 48c >ALC.EB

Peer Vergelijking

Prijswijziging

Cencora Inc Prognose

Koersdoel

By TipRanks

7.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 393.78 USD  7.99%

Hoogste 417 USD

Laagste 361 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cencora Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Sentiment

By Acuity

163 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat